R Squared’s Larimar Therapeutics LRMR Stock Holding History

R Squared’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-720	Closed	-$2.79K	–	960
2024 Q4	$2.79K	Buy	+720	New	+$4.75K	﹤0.01%	1423

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

R Squared's LRMR Position: Q1 2025 in Review

R Squared sold out of Larimar Therapeutics (LRMR) in Q1 2025, closing a stake of 720 shares — an estimated $2.79K sold.

R Squared first reported a position in LRMR in Q4 2024 and held it in 1 quarter. The position peaked at $2.79K in Q4 2024. 103 funds tracked by Wall St. Rank hold LRMR as of Q1 2025.

R Squared reported no remaining Larimar Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 720 Larimar Therapeutics shares in Q1 2025, an estimated $2.79K.
R Squared first reported a position in Larimar Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Larimar Therapeutics position peaked at $2.79K in Q4 2024.
103 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.